about
Protein carbamylation and cardiovascular diseaseThe kidney in congestive heart failure: 'are natriuresis, sodium, and diuretics really the good, the bad and the ugly?'The polycompartment syndrome: a concise state-of-the-art reviewManagement of the cardiorenal syndrome in decompensated heart failureGlobal myocardial oedema in advanced decompensated heart failure.Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failureMitral valve area during exercise after restrictive mitral valve annuloplasty: importance of diastolic anterior leaflet tethering.Response and tolerance to oral vasodilator up-titration after intravenous vasodilator therapy in advanced decompensated heart failure.Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failureAbdominal contributions to cardiorenal dysfunction in congestive heart failure.The pathophysiological role of interstitial sodium in heart failure.Hyponatremia in acute decompensated heart failure: depletion versus dilution.What do small serum creatinine changes tell us about outcomes after acute myocardial infarction?Protocol-driven remote monitoring of cardiac resynchronization therapy as part of a heart failure disease management strategy.Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction.Renal sodium avidity in heart failure: from pathophysiology to treatment strategies.Etiology and relevance of the figure-of-eight artifact on echocardiography after percutaneous left atrial appendage closure with the Amplatzer Cardiac Plug.No arguments for increased endothelial nitric oxide synthase activity in migraine based on peripheral biomarkers.Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.Increasing diuresis in congestive heart failure: ready for prime time?Clinical outcomes after tricuspid valve annuloplasty in addition to mitral valve surgery.Cardiac resynchronization therapy with or without defibrillator: experience from a high-volume Belgian implantation centre.Bioimpedance Alerts from Cardiovascular Implantable Electronic Devices: Observational Study of Diagnostic Relevance and Clinical Outcomes.Value of routine investigations to predict loop diuretic down-titration success in stable heart failure.Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy.Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low.Urinary composition during decongestive treatment in heart failure with reduced ejection fraction.Limited contractile reserve contributes to poor peak exercise capacity in iron-deficient heart failure.Plasma Volume Is Normal but Heterogeneously Distributed, and True Anemia Is Highly Prevalent in Patients With Stable Heart Failure.Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions.Feasibility and Association of Neurohumoral Blocker Up-titration After Cardiac Resynchronization Therapy.The figure-of-eight artifact in the echocardiographic assessment of percutaneous disc occluders: impact of imaging depth and device type.Mode of Death in Octogenarians Treated With Cardiac Resynchronization Therapy.Combined management of atrial fibrillation and heart failure: case studies.Diuretics in cardiorenal syndrome: what's new?Asymptomatic episodes of device-registered atrial tachyarrhythmia are not associated with worse cardiac resynchronization therapy response.Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome.Selective abdominal venous congestion to investigate cardiorenal interactions in a rat model.Effect of Cardiac Resynchronization Therapy on Exercise-Induced Pulmonary Hypertension and Right Ventricular-Arterial Coupling
P50
Q26827410-AC6BF770-2E82-4D2B-8381-23949FD69EEFQ27011043-9FFC05E6-2893-4236-9252-3E81937B4090Q27015659-342517E6-93CB-467B-BC0B-94C711F10DA2Q27028203-75C6438F-22B7-48AA-A8B2-672C81C73262Q31112487-B68546E9-E071-4E7C-97D1-2B840974F6D7Q33793230-C089FB0B-882D-46C3-A58A-558A9A5E9DEDQ35212907-70D408E6-4F4C-4D66-BB8D-C2D047AF3491Q36302339-514433EA-C7EA-4AB5-ACFC-3836D6154D0BQ37194692-C0F32E56-213A-44C2-AE1C-71B6FD93BCFCQ38112972-0829D6B9-DA6C-4883-B07D-3C7D84E7552EQ38337332-5E17F445-8808-4726-A167-62FAFF656F4BQ38347429-449829D9-3CF6-4F4C-ACC0-1E194B62739EQ38604135-CCC0F71A-D0F6-46EA-AA6D-4E6155B0B3D1Q38643262-05D7922F-2E58-482D-9AEB-9EC7A31A2914Q38668459-3AF5B933-24CD-4032-A49F-04EA70A2EA2AQ39193458-86AD40C8-2553-42FA-80DC-696502601076Q39293200-6A870968-4B4C-4890-AE21-576D72C55514Q42854060-ABEF1A98-2397-4025-A3AD-9213710E27C0Q43678773-1305985A-F707-4E54-9984-2DBD618909B9Q44698052-CE2C5F35-2199-49A7-9CB7-2F736F59A418Q45327598-C6006605-EA5F-4415-88D8-ADB7EC6C1089Q46029348-F7DC4AEA-A240-4120-B8B4-ACDF920352CBQ47093541-AD449230-C528-4258-B12C-9B6DEA9F00F2Q47748047-EE2C5050-D093-441F-8588-7D829CF5E814Q47898606-14B8C016-1256-455D-A433-E5C48BA745FAQ47913662-84DC8695-88CE-4880-814E-0A2D2F375206Q48254543-E210DFFC-2334-4618-B9E6-0C03ACD5F71FQ48846583-859983B7-A8F8-446E-A845-E1E916AFAB57Q50027168-87FBAEF5-126D-44BA-9D2E-E6BFE927CB73Q50230133-485A51F5-4EBE-4B8B-8133-B47352841292Q50630775-508B1403-032F-4A91-8584-BC3B3C046250Q50849493-6E47AE12-F28A-479E-BAB1-02788D65F911Q51065510-05E28E94-EC51-4C78-84BA-DC18F75A9695Q51321814-DEB7BA1E-3BF2-4F0E-9962-96F63460CA27Q51778723-42AE5F37-8535-4C7D-816A-4B8B943441B7Q53282871-4E9CD2FF-41DA-4B89-972E-C4279F9B374FQ53627570-B284D41D-5C61-4F09-9569-EC41E2722358Q53834597-0A2A3A7D-C755-4847-AA5C-788DB81B9117Q55110455-3D3D058C-9A2F-456E-A3A3-9E24C6246664Q57822611-2A0F191E-2042-4CCD-BF34-E55886DF3E95
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Frederik H Verbrugge
@ast
Frederik H Verbrugge
@en
Frederik H Verbrugge
@es
Frederik H Verbrugge
@nl
type
label
Frederik H Verbrugge
@ast
Frederik H Verbrugge
@en
Frederik H Verbrugge
@es
Frederik H Verbrugge
@nl
prefLabel
Frederik H Verbrugge
@ast
Frederik H Verbrugge
@en
Frederik H Verbrugge
@es
Frederik H Verbrugge
@nl
P108
P106
P1153
36176583600
P21
P31
P496
0000-0003-0599-9290